

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/079868 A2

(51) International Patent Classification⁷: **A61K 51/04**,
31/519, 31/4985, C07D 487/04, 471/16, A61P 5/02

John [US/US]; Neurocrine Biosciences Inc, 12790 El
Camino Real, San Diego, CA 92130 (US).

(21) International Application Number:
PCT/GB2005/000432

(74) Agent: **DOLTON, Peter**; GlaxoSmithKline, CN925.1,
980 Great West Road, Brentford, Middlesex TW8 9GS
(GB).

(22) International Filing Date: 9 February 2005 (09.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/544,758 13 February 2004 (13.02.2004) US

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicants (*for all designated States except US*): **SB
PHARMCO PUERTO RICO INC** [US/US]; The Pre-
ntice Hall Corp. System of PR Inc, c/o FGR Corporate
Services Inc, BBV Tower 8th Floor, 254 Munoz Rivera
Avenue, San Juan, PUERTO RICO 009 (US). **NEURO-
CRINE BIOSCIENCES INC** [US/US]; 12790 El Camino
Real, San Diego, California 92130 (US).

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **GLAXO GROUP LIMITED**
[GB/GB]; Glaxo Wellcome House, Berkeley Avenue,
Greenford Middlesex UB6 0NN (GB).

Published:

— *without international search report and to be republished
upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SLEE, Deborah**
[US/US]; Neurocrine Biosciences Inc, 12790 El Camino
Real, San Diego, California 92130 (US). **GRIGORIADIS,
Dimitri** [CA/US]; Neurocrine Biosciences Inc, 12790 El
Camino Real, San Diego, CA 92130 (US). **WILLIAMS,**

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: CRF RECEPTOR ANTAGONISTS, THEIR PREPARATIONS, THEIR PHARMACEUTICAL COMPOSITION AND
THEIR USES

(57) Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the
treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals. CRF receptor antagonists which are labeled
with a positron emitting isotope for use in PET are also disclosed.



WO 2005/079868 A2